CRXM nice 8k out Gene Biotherapeutics Inc. (OTC: CRXM) announced today that it has entered into an agreement with FUJIFILM Diosynth Biotechnologies (“FDB”) to manufacture the Generx [Ad5FGF-4] angiogenic gene therapy product candidate for Phase 3 clinical evaluation for the treatment of refractory angina due to late-stage coronary artery disease.
https://www.otcmarkets.com/filing/html?id=148...Fu76bTHLth